Published in Oncologist on December 01, 2007
Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol (2009) 4.82
NCCN clinical practice guidelines in oncology: hepatobiliary cancers. J Natl Compr Canc Netw (2009) 3.25
Astrocyte elevated gene-1 regulates hepatocellular carcinoma development and progression. J Clin Invest (2009) 2.79
Identification of genes conferring resistance to 5-fluorouracil. Proc Natl Acad Sci U S A (2009) 1.92
A randomised phase II study of pegylated arginine deiminase (ADI-PEG 20) in Asian advanced hepatocellular carcinoma patients. Br J Cancer (2010) 1.23
AEG-1/MTDH/LYRIC in liver cancer. Adv Cancer Res (2013) 1.01
The transcription factor LSF: a novel oncogene for hepatocellular carcinoma. Am J Cancer Res (2012) 0.93
Knockdown of β-catenin with dicer-substrate siRNAs reduces liver tumor burden in vivo. Mol Ther (2013) 0.91
Efficacy of TACE in TIPS patients: comparison of treatment response to chemoembolization for hepatocellular carcinoma in patients with and without a transjugular intrahepatic portosystemic shunt. Cardiovasc Intervent Radiol (2013) 0.89
A randomized phase II study of autologous cytokine-induced killer cells in treatment of hepatocellular carcinoma. J Clin Immunol (2013) 0.89
Laparoscopic radiofrequency ablation of unresectable hepatocellular carcinoma: long-term follow-up. HPB (Oxford) (2008) 0.84
18F-Fluorodeoxyglucose positron emission tomography for monitoring response to sorafenib treatment in patients with hepatocellular carcinoma. Oncologist (2008) 0.83
Repeated transcatheter arterial chemoembolization is safe for hepatocellular carcinoma in cirrhotic patients with transjugular intrahepatic portosystemic shunt. Diagn Interv Radiol (2014) 0.83
Knockdown of astrocyte elevated gene-1 inhibits growth through suppression of IL-6 secretion in HepG2 human hepatoma cells. Oncol Lett (2013) 0.82
Metronomic chemotherapy: possible clinical application in advanced hepatocellular carcinoma. Transl Oncol (2013) 0.81
GRP78 confers the resistance to 5-FU by activating the c-Src/LSF/TS axis in hepatocellular carcinoma. Oncotarget (2015) 0.79
Eastern Asian expert panel opinion: designing clinical trials of molecular targeted therapy for hepatocellular carcinoma. BMC Cancer (2010) 0.79
The role of AEG-1 in the development of liver cancer. Hepat Oncol (2016) 0.78
β-Elemene Inhibits Cell Proliferation by Regulating the Expression and Activity of Topoisomerases I and IIα in Human Hepatocarcinoma HepG-2 Cells. Biomed Res Int (2015) 0.77
Survival Analysis of Single Large (>5 cm) Hepatocellular Carcinoma Patients: BCLC A versus B. PLoS One (2016) 0.75
Transarterial therapy: an evolving treatment modality of hepatocellular carcinoma. Saudi J Gastroenterol (2014) 0.75
DNA Alkylating Agent Protects Against Spontaneous Hepatocellular Carcinoma Regardless of O6-Methylguanine-DNA Methyltransferase Status. Cancer Prev Res (Phila) (2015) 0.75
NCCN Clinical Practice Guidelines in Oncology: colon cancer. J Natl Compr Canc Netw (2009) 4.41
NCCN Clinical Practice Guidelines in Oncology: rectal cancer. J Natl Compr Canc Netw (2009) 3.37
NCCN clinical practice guidelines in oncology: hepatobiliary cancers. J Natl Compr Canc Netw (2009) 3.25
American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes. J Clin Oncol (2014) 3.20
High incidence of cetuximab-related infusion reactions in Tennessee and North Carolina and the association with atopic history. J Clin Oncol (2007) 2.99
Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors. J Clin Oncol (2006) 1.86
Phase II study of fixed dose rate gemcitabine with cisplatin for metastatic adenocarcinoma of the pancreas. J Clin Oncol (2005) 1.78
Colon cancer, version 3.2014. J Natl Compr Canc Netw (2014) 1.59
Treatment of intermediate/advanced hepatocellular carcinoma in the clinic: how can outcomes be improved? Oncologist (2010) 1.59
A phase II study of fixed-dose rate gemcitabine plus low-dose cisplatin followed by consolidative chemoradiation for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys (2007) 1.53
Chemotherapy and regional therapy of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol (2006) 1.52
Clinical utility of AFP-L3% measurement in North American patients with HCV-related cirrhosis. Am J Gastroenterol (2007) 1.49
Rectal cancer. J Natl Compr Canc Netw (2012) 1.49
A phase II prospective multi-institutional trial of adjuvant active specific immunotherapy following curative resection of colorectal cancer hepatic metastases: cancer and leukemia group B study 89903. Ann Surg Oncol (2007) 1.46
Borderline resectable pancreatic cancer: need for standardization and methods for optimal clinical trial design. Ann Surg Oncol (2013) 1.36
Metastatic colon cancer, version 3.2013: featured updates to the NCCN Guidelines. J Natl Compr Canc Netw (2013) 1.31
A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic cancer: is an anti-VEGF strategy still applicable? Invest New Drugs (2008) 1.30
Nonoperative therapies for combined modality treatment of hepatocellular cancer: expert consensus statement. HPB (Oxford) (2010) 1.30
Identification of unknown primary tumors in patients with neuroendocrine liver metastases. Arch Surg (2010) 1.29
When progressive disease does not mean treatment failure: reconsidering the criteria for progression. J Natl Cancer Inst (2012) 1.28
Utility of Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein and des-gamma-carboxy prothrombin, alone or in combination, as biomarkers for hepatocellular carcinoma. Clin Gastroenterol Hepatol (2008) 1.26
Hepatocellular carcinoma: regional therapy with a magnetic targeted carrier bound to doxorubicin in a dual MR imaging/ conventional angiography suite--initial experience with four patients. Radiology (2004) 1.19
Colon cancer clinical practice guidelines in oncology. J Natl Compr Canc Netw (2005) 1.19
Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: results from CALGB80303 (Alliance). Clin Cancer Res (2013) 1.18
Localized colon cancer, version 3.2013: featured updates to the NCCN Guidelines. J Natl Compr Canc Netw (2013) 1.17
Serum CA19-9 decline compared to radiographic response as a surrogate for clinical outcomes in patients with metastatic pancreatic cancer receiving chemotherapy. Pancreas (2008) 1.15
A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer. Cancer Chemother Pharmacol (2010) 1.15
Clinicopathologic characteristics and survival outcomes of patients with fibrolamellar carcinoma: data from the fibrolamellar carcinoma consortium. Gastrointest Cancer Res (2013) 1.13
A Phase II Study of Long-Acting Octreotide in Patients With Advanced Hepatocellular Carcinoma and CLIP Score of 3 or Higher. Gastrointest Cancer Res (2009) 1.12
Efficacy and safety of liposomal anthracyclines in phase I/II clinical trials. Semin Oncol (2004) 1.10
Relationship between statin use and colon cancer recurrence and survival: results from CALGB 89803. J Natl Cancer Inst (2011) 1.06
The cancer and leukemia group B pharmacology and experimental therapeutics committee: a historical perspective. Clin Cancer Res (2006) 1.05
Prognostic and predictive markers in stage II colon cancer: is there a role for gene expression profiling? Clin Colorectal Cancer (2011) 1.04
Perineural invasion in pT3N0 rectal cancer: the incidence and its prognostic effect. Cancer (2010) 1.02
NCCN clinical practice guidelines in oncology. Anal carcinoma. J Natl Compr Canc Netw (2010) 1.00
The antiangiogenic ceiling in hepatocellular carcinoma: does it exist and has it been reached? Lancet Oncol (2013) 1.00
Biomarker use in colorectal cancer therapy. J Natl Compr Canc Netw (2011) 0.99
Frequency of hepatic contour abnormalities and signs of portal hypertension at CT in patients receiving chemotherapy for breast cancer metastatic to the liver. Clin Imaging (2006) 0.98
NCCN Task Force Report: mTOR inhibition in solid tumors. J Natl Compr Canc Netw (2008) 0.97
Colon cancer. J Natl Compr Canc Netw (2011) 0.96
Anal Carcinoma, Version 2.2012: featured updates to the NCCN guidelines. J Natl Compr Canc Netw (2012) 0.96
Personalized medicine and oncology practice guidelines: a case study of contemporary biomarkers in colorectal cancer. J Natl Compr Canc Netw (2011) 0.95
Lymph node sampling rates and predictors of nodal metastasis in pancreatic neuroendocrine tumor resections: the UCSF experience with 149 patients. Pancreas (2012) 0.94
Fractional genomic alteration detected by array-based comparative genomic hybridization independently predicts survival after hepatic resection for metastatic colorectal cancer. Clin Cancer Res (2005) 0.94
Excess toxicity associated with docetaxel and irinotecan in patients with metastatic, gemcitabine-refractory pancreatic cancer: results of a phase II study. Cancer Invest (2008) 0.94
Sorafenib in hepatocellular carcinoma: separating the hype from the hope. J Clin Oncol (2008) 0.94
Predictive biomarkers for bevacizumab: are we there yet? Clin Cancer Res (2013) 0.94
Hepatobiliary cancers, version 2.2014. J Natl Compr Canc Netw (2014) 0.93
Rectal cancer clinical practice guidelines in oncology. J Natl Compr Canc Netw (2005) 0.92
The impact of new data in the treatment of advanced hepatocellular carcinoma. Curr Oncol Rep (2008) 0.92
Hepatobiliary cancers. Clinical practice guidelines in oncology. J Natl Compr Canc Netw (2006) 0.90
Colon cancer. J Natl Compr Canc Netw (2007) 0.87
NCCN Working Group report: designing clinical trials in the era of multiple biomarkers and targeted therapies. J Natl Compr Canc Netw (2014) 0.86
Nonadherence to imatinib during an economic downturn. N Engl J Med (2010) 0.86
Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw (2017) 0.83
Adjuvant and neoadjuvant therapy for esophageal cancer: a critical reappraisal. Surg Oncol (2003) 0.83
Targeted therapy in colorectal cancer. Clin Adv Hematol Oncol (2006) 0.82
Optimizing the administration of fixed-dose rate gemcitabine plus capecitabine using an alternating-week schedule: a dose finding and early efficacy study in advanced pancreatic and biliary carcinomas. Am J Clin Oncol (2012) 0.82
International adaptations of NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw (2014) 0.81
Metastatic colorectal cancer: a curable disease. Oncology (Williston Park) (2012) 0.81
Rectal cancer. J Natl Compr Canc Netw (2007) 0.81
Development of a research agenda for the management of metastatic colorectal cancer: proceedings from a multidisciplinary research consensus panel. J Vasc Interv Radiol (2012) 0.80
Design issues in dose-finding Phase I trials for combinations of two agents. J Biopharm Stat (2009) 0.80
Long-term outcome of early-stage rectal cancer undergoing standard resection and local excision. Clin Colorectal Cancer (2011) 0.79
Predictive biomarkers in advance of a companion drug: ahead of their time? J Natl Compr Canc Netw (2012) 0.79
Curable patient with metastatic colorectal cancer: balancing effective therapies and toxicities. J Clin Oncol (2014) 0.78
Can we cure cholangiocarcinoma with neoadjuvant chemoradiation and liver transplantation? Time for a multicenter trial. Liver Transpl (2012) 0.78
Identification of potential prognostic biomarkers in patients with untreated, advanced pancreatic cancer from a phase 3 trial (Cancer and Leukemia Group B 80303). Cancer (2011) 0.78
A Phase I Study of FOLFIRINOX Plus IPI-926, a Hedgehog Pathway Inhibitor, for Advanced Pancreatic Adenocarcinoma. Pancreas (2016) 0.78
Comparison of dietary and lifestyle habits among stage III and metastatic colorectal cancer patients: findings from CALGB 89803 and CALGB 80405. Clin Colorectal Cancer (2013) 0.77
Anal canal cancer clinical practice guidelines in oncology. J Natl Compr Canc Netw (2005) 0.77
Drug development in advanced colorectal cancer: challenges and opportunities. Curr Oncol Rep (2009) 0.77
Novel therapeutics in hepatocellular carcinoma: how can we make progress? Am Soc Clin Oncol Educ Book (2013) 0.77
Adjuvant treatment of colon cancer: what is next? Curr Opin Oncol (2011) 0.77
90Y glass microspheres for the treatment of unresectable metastatic liver disease from chemotherapy-refractory gastrointestinal cancers: a pilot study. J Gastrointest Cancer (2014) 0.76
An alternative therapy for patients with hepatic impairment? Onkologie (2007) 0.75
Section I: essentials of ensuring excellence in cancer care. Gastrointest Cancer Res (2007) 0.75
Section IV: Significance of Recent Study Results and Future Research Directions in Gastrointestinal Oncology. Gastrointest Cancer Res (2007) 0.75
Responding to the rising incidence of hepatocellular carcinoma with targeted therapy. Gastrointest Cancer Res (2008) 0.75
Counterpoint: Adjuvant therapy in stage II colon cancer: pain not justified by the gain. J Natl Compr Canc Netw (2012) 0.75
Testing the water before diving off the cutting edge. Ann Surg Oncol (2003) 0.75
Section III: Treatment of Advanced Gastrointestinal Cancers. Gastrointest Cancer Res (2007) 0.75
Shedding old paradigms: developing viruses to treat cancer. J Clin Oncol (2002) 0.75
Biomarkers in colon cancer: the chasm between expectations and reality. Oncology (Williston Park) (2013) 0.75
Lactic acidosis and colon cancer: oncologic emergency? Clin Colorectal Cancer (2011) 0.75
Hepatocellular Carcinoma: Contemporary Diagnosis, Investigation and Management. J Natl Cancer Inst (2000) 0.75
Systemic and regional nonsurgical therapy--what is the optimal strategy for metastatic neuroendocrine cancer? Surg Oncol Clin N Am (2007) 0.75
The Developing Role of Anti-Epidermal Growth Factor Receptor Agents in the Treatment of Advanced or Metastatic Colorectal Cancer. Oncology (Williston Park) (2017) 0.75
Cetuximab in the treatment of colorectal cancer. Clin Adv Hematol Oncol (2004) 0.75
"And what other medications are you taking?". J Clin Oncol (2011) 0.75
Oxaliplatin-Fluoropyrimidine Chemotherapy Plus Bevacizumab in Advanced Neuroendocrine Tumors: An Analysis of 2 Phase II Trials. Pancreas (2016) 0.75